コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 l responses is desired (ie, in anti-viral or anti-tumor immunity).
2 ance promote T cell self-renewal and enhance anti-tumor immunity.
3 astatic niche formation and the induction of anti-tumor immunity.
4 ved to be a major contributor to compromised anti-tumor immunity.
5 promoting T cell function, autoimmunity, and anti-tumor immunity.
6 ting T cell function during autoimmunity and anti-tumor immunity.
7 glucose availability to T cells, suppressing anti-tumor immunity.
8 in tumor-infiltrating dendritic cells blunts anti-tumor immunity.
9 varian cancer (OvCa) progression by blunting anti-tumor immunity.
10 alignant melanoma, by impeding IgG1-mediated anti-tumor immunity.
11 l of cancer cells, as well as in suppressing anti-tumor immunity.
12 mal tissues function in parallel to restrict anti-tumor immunity.
13 lly provide therapeutic benefit by enhancing anti-tumor immunity.
14 and are important targets of T cell-mediated anti-tumor immunity.
15 the tumor microenvironment that can suppress anti-tumor immunity.
16 into the mechanism by which OX40 may impact anti-tumor immunity.
17 seek to reverse this phenomenon and promote anti-tumor immunity.
18 ancer membrane target antigens using humoral anti-tumor immunity.
19 ls into the tumor microenvironment restrains anti-tumor immunity.
20 earch indicates that B cells are involved in anti-tumor immunity.
21 ze SERCA function to disable T cell-mediated anti-tumor immunity.
22 miting the generation of innate and adaptive anti-tumor immunity.
23 ion, regulating the balance between pro- and anti-tumor immunity.
24 is the bottleneck, which precludes efficient anti-tumor immunity.
25 es rapid vessel loss, which does not support anti-tumor immunity.
26 nisms of immunosuppression hinder productive anti-tumor immunity.
27 Treg cells into tumor-bearing mice enhanced anti-tumor immunity.
28 s NK cells and augments antigen-specific CTL anti-tumor immunity.
29 nting DCs strongly enhances antigen-specific anti-tumor immunity.
30 rived cytokines with the capacity to augment anti-tumor immunity.
31 critical role in both afferent and efferent anti-tumor immunity.
32 e balance of the immune response in favor of anti-tumor immunity.
33 F-beta signaling leads to the enhancement of anti-tumor immunity.
34 oidogenesis pathway is sufficient to restore anti-tumor immunity.
35 ciated antigens for the induction of in vivo anti-tumor immunity.
36 an important role in immune surveillance and anti-tumor immunity.
37 ce protective, antigen-specific CTL-mediated anti-tumor immunity.
38 ry strategies aimed at inducing antiviral or anti-tumor immunity.
39 ce may be key in the generation of effective anti-tumor immunity.
40 egs disrupted immune homeostasis but boosted anti-tumor immunity.
41 rs offers a promising alternative to enhance anti-tumor immunity.
42 ivarius and Bacteroides plebeius may inhibit anti-tumor immunity.
43 lve inflammation, repair tissue, and augment anti-tumor immunity.
44 tion, suggesting that they may be primed for anti-tumor immunity.
45 on CD8(+) T cells, which are key players in anti-tumor immunity.
46 nd activated IRF4-driven macrophage-mediated anti-tumor immunity.
47 compatibility complex (MHC) is essential for anti-tumor immunity.
48 effects in allergic airway inflammation and anti-tumor immunity.
49 cell dependent fashion, confirming long-term anti-tumor immunity.
50 natural killer (NK) cells and macrophages in anti-tumor immunity.
51 overexpressed on tumor cells that suppresses anti-tumor immunity.
52 CD8(+) T cell responses are critical for anti-tumor immunity.
53 CD8(+) T cells play an important role in anti-tumor immunity.
54 killer (NK) cell activity, thereby limiting anti-tumor immunity.
55 Cancer expression of PD-L1 suppresses anti-tumor immunity.
56 toxin treatment, suggesting the induction of anti-tumor immunity.
57 ological consequences on autoimmunity versus anti-tumor immunity.
58 (+) Th1 effector cells contribute to optimal anti-tumor immunity.
59 Cytotoxic T cells are important effectors of anti-tumor immunity.
60 vo steroidogenesis in T lymphocytes to evade anti-tumor immunity.
61 Cs enhances their maturation, thus improving anti-tumor immunity.
62 une responses, which initiate and coordinate anti-tumor immunity.
63 growth in mice and synergistically enhances anti-tumor immunity.
64 ustly activate the immune system and promote anti-tumor immunity.
65 Furthermore, Mertk KO mice display improved anti-tumor immunity.
66 reduced tumor incidence/growth and increased anti-tumor immunity.
67 ease stemness of CD8(+) T cells and augments anti-tumor immunity.
68 olecules, is also important in orchestrating anti-tumor immunity.
69 Bcl2l1, and examined their contributions to anti-tumor immunity.
70 nctional switch controlling TAM function and anti-tumor immunity.
71 (PERK) in cancer cells in the modulation of anti-tumor immunity.
72 mpact of fasting on natural killer (NK) cell anti-tumor immunity.
73 d CCL5 repression is critical for modulating anti-tumor immunity.
74 te homologous recombination repair (HRR) and anti-tumor immunity.
75 ndergoes cleavage by ADAM17 that dampens its anti-tumor immunity.
76 e cells simultaneously, which can compromise anti-tumor immunity.
77 elease and protective CD8(+) T cell-mediated anti-tumor immunity.
78 es to enhance both intratumoral and systemic anti-tumor immunity.
79 vironment, and IFN-gamma is instrumental for anti-tumor immunity.
80 persist post-surgery and continue to impair anti-tumor immunity.
81 n, thereby augmenting CD8(+) T-cell-mediated anti-tumor immunity.
82 ognostic biomarker and therapeutic target in anti-tumor immunity.
83 controls ICI-induced irAEs without blocking anti-tumor immunity.
84 amming by tumor cells in obese mice improves anti-tumor immunity.
85 essing dendritic cells (DCs) as enhancers of anti-tumor immunity.
86 d NK cell survival, signal transduction, and anti-tumor immunity.
87 ulator interleukin-33 (Il33), which controls anti-tumor immunity.
88 ost responses to infection, inflammation and anti-tumor immunity.
89 o favor tumor growth by negatively affecting anti-tumor immunity.
90 ory mediators and triggered T cell-dependent anti-tumor immunity.
91 or in Cd27(-/-) mice, did not further impair anti-tumor immunity.
92 and immune checkpoint blockade (ICB)-induced anti-tumor immunity.
93 c lethality, hence impairing STING-dependent anti-tumor immunity.
94 g cells restored tumor growth and attenuated anti-tumor immunity.
95 ce and partially restored CD8 metabolism and anti-tumor immunity.
96 ng the suppressive immune landscape to favor anti-tumor immunity.
97 netic redundancy accounts for the absence of anti-tumor immunity.
98 tle is known about the effects of obesity on anti-tumor immunity.
99 tumor cells is essential for dMMR-triggered anti-tumor immunity.
100 and the PD-L1 checkpoint inhibitor augments anti-tumor immunity.
101 n the breast TME and unleashes host adaptive anti-tumor immunity.
102 potent immunosuppressive functions hindering anti-tumor immunity.
103 linical success by blocking amplification of anti-tumor immunity.
104 able better strategies to restore protective anti-tumor immunity.
105 melanoma progression was mediated by altered anti-tumor immunity.
106 ides substantial room for engineering better anti-tumor immunity.
107 ng new insights into the regulation of human anti-tumor immunity.
108 responses through DCs, thereby strengthening anti-tumor immunity.
109 austion of CD8(+) TILs that limits effective anti-tumor immunity.
110 overlapping but non-redundant regulation of anti-tumor immunity.
111 g between cancer-associated inflammation and anti-tumor immunity.
112 an important role for the gut microbiome in anti-tumor immunity.
113 t to implanted tumors and displayed enhanced anti-tumor immunity.
114 ly replicates in cancer cells while inducing anti-tumor immunity.
115 -activating TLR4 agonist capable of inducing anti-tumor immunity.
116 (Th1) immune responses that are required for anti-tumor immunity.
117 iggers Treg instability locally and restores anti-tumor immunity.
118 a pathophysiological context: suppression of anti-tumor immunity.
119 ntion of autoimmunity and the suppression of anti-tumor immunity.
120 r-infiltrating T cells results in diminished anti-tumor immunity.
121 Regulatory T cells (Tregs) are a barrier to anti-tumor immunity.
122 vitamin D signaling in humans could suppress anti-tumor immunity.
123 hibitory Siglecs that can potentially dampen anti-tumor immunity.
124 e attenuation as well as the facilitation of anti-tumor immunity.
125 cells and their ability to induce efficient anti-tumor immunity.
126 reprogrammed into indispensable mediators of anti-tumor immunity.
127 nogenicity and its role in the activation of anti-tumor immunity.
128 une disease and graft rejection and promotes anti-tumor immunity.
129 austion ligands and thereby negated adaptive anti-tumor immunity.
130 ion of tumor antigens and thereby stimulates anti-tumor immunity.
131 ted role of the Hippo pathway in suppressing anti-tumor immunity.
132 modeling, and impairment of T cell-dependent anti-tumor immunity.
133 tes to reveal a role for zinc homeostasis in anti-tumor immunity.
134 reg) cells pose a major barrier to effective anti-tumor immunity.
135 ific alphabeta T cell receptor (TCR) mediate anti-tumor immunity.
136 or psoriasis, but pDCs are also involved in (anti-)tumor immunity.
137 liver X receptors, previously shown to boost anti-tumor immunity(4), exhibited therapeutic efficacy i
140 resent tumor-associated antigens for in vivo anti-tumor immunity against challenge with the S1509a sp
141 seful for enlisting the help of DCs to boost anti-tumor immunity against local and metastatic tumors
142 ressed ISG(+) DCs by exogenous IFN-B rescued anti-tumor immunity against progressor tumors in Batf3(-
143 sed ISG(+) DCs by exogenous IFN-beta rescued anti-tumor immunity against progressor tumors in Batf3(-
144 ellular immunity and failed cytotoxic T cell anti-tumor immunity, alter cancer risk and therefore rep
145 cells are important and potent mediators of anti-tumor immunity and adoptive transfer of specific CD
146 translatable strategy to potentiate adaptive anti-tumor immunity and augment response to ICB or poten
147 cells by T cells is a critical mechanism of anti-tumor immunity and cancer immunotherapy response.
148 ly unappreciated roles for IL-35 in limiting anti-tumor immunity and contributing to T cell dysfuncti
149 the complexity of functions for IFN-gamma in anti-tumor immunity and demonstrate that intratumor hete
150 rtance of molecular diversity as a driver of anti-tumor immunity and discuss how these factors can be
151 e impact of melanoma metabolic adaptation on anti-tumor immunity and discuss how to counteract such m
152 emonstrate that targeting KDM4A can activate anti-tumor immunity and enable PD1 blockade immunotherap
153 gnaling pathways, can contribute to decrease anti-tumor immunity and enhance cell proliferation and o
154 stress responses to reinvigorate endogenous anti-tumor immunity and enhance the efficacy of various
155 umor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival.
156 in combination with FAK, can drive enhanced anti-tumor immunity and even complete regression of muri
157 t a pro-inflammatory environment may curtail anti-tumor immunity and favor cancer initiation and prog
158 correlate with the development of productive anti-tumor immunity and greater efficacy of PD1 immunoth
159 lative contribution of CD8(+) T(RM) cells to anti-tumor immunity and immune checkpoint blockade effic
160 ve resource toward a deeper understanding of anti-tumor immunity and immuno-oncology drug development
161 ustrate that the systemic context can impact anti-tumor immunity and immunotherapy responsiveness.
163 Tim-3(+)CD8(+) T cells can promote effective anti-tumor immunity and implicate PTPN2 in immune cells
164 increased CD226 surface expression, enhanced anti-tumor immunity and improved efficacy of immune chec
165 per T (Th9) cells are essential for inducing anti-tumor immunity and inflammation in allergic and aut
166 ification of parameters underlying effective anti-tumor immunity and is available to the research com
167 for the stimulation of CD4+ T cell dependent anti-tumor immunity and may play a role in tumor surveil
168 and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressio
169 ulates the redox balance in the TME to boost anti-tumor immunity and prolong the survival of tumor-be
171 stress increases innate sensing and adaptive anti-tumor immunity and provide strong rationales for co
172 ty acid elongation for AA synthesis restores anti-tumor immunity and re-sensitizes the resistant tumo
173 ckdown of ZDHHC3 in tumors results in robust anti-tumor immunity and reduces tumor progression in mur
175 ium, enriched in Rnf5(-/-) mice, establishes anti-tumor immunity and restricts melanoma growth in ger
176 ficance as a therapeutic approach to augment anti-tumor immunity and sensitize ICB-based cancer immun
177 3 with other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in sever
178 b deletion in melanoma-bearing mice enhances anti-tumor immunity and synergizes with anti-PD-L1 thera
179 sum, immunotoxin-mediated cell death induces anti-tumor immunity and the development of TLS, which pr
182 using of Rnf5(-/-) and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, wher
183 trated that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD4(+) and CD8(+) T cel
184 ility of surrounding wild-type Tregs, boosts anti-tumor immunity, and facilitates tumor clearance.
186 mework, mutational load, immune composition, anti-tumor immunity, and immunosuppressive escape mechan
188 and activity of cytotoxic T cells, enhances anti-tumor immunity, and overcomes resistance to ICB the
190 tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/P
191 r-derived Ags leading to long-lived systemic anti-tumor immunity, and suggests a paradigm for clinica
192 yte-derived cells, enhances T cell-dependent anti-tumor immunity, and synergizes with immune checkpoi
195 ntributes to the protection against the host anti-tumor immunity as well as to the survival of invadi
196 generates bona fide neoantigens and elicits anti-tumor immunity, augmenting checkpoint immunotherapy
197 mphocytes (CTLs) are key players of adaptive anti-tumor immunity based on their ability to specifical
198 Finally, we find that muMT mice display anti-tumor immunity because of an unexpected compensator
199 al killer (NK) cells exert critical roles in anti-tumor immunity but how their functions are regulate
201 ens for the induction of substantial in vivo anti-tumor immunity but only after activation in vitro b
202 wart their pro-cancer activities and unleash anti-tumor immunity, but efforts to accomplish this are
203 ic blockade of PD-1 enhances T cell-mediated anti-tumor immunity, but many patients do not respond an
206 ndritic cells (cDC1s) control anti-viral and anti-tumor immunity by inducing antigen-specific cytotox
207 ents with immunogenic properties may enhance anti-tumor immunity by inducing autophagic cell death.
208 s, and may lead to a new strategy to restore anti-tumor immunity by inhibiting pathways of force-gene
211 we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopept
214 ed peptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward
215 Modulation of the immune system to amplify anti-tumor immunity carries the risk of developing autoi
216 g host defense against microbial infections, anti-tumor immunity, cellular senescence, autophagy, and
217 vivo, restoration of TTP expression enhances anti-tumor immunity dependent on degradation of PD-L1 mR
219 a mature immune system, we detect measurable anti-tumor immunity from very early stages, which is dri
220 temness and invasion programs while inducing anti-tumor immunity genes and may therefore restrain mal
221 landscape of a tumor shapes and is shaped by anti-tumor immunity has not been systematically explored
224 ctivation of the cGAS pathway is crucial for anti-tumor immunity; however, no effective intervention
225 ells share many phenotypes and functions for anti-tumor immunity; however, the dynamic changes in phe
227 ted control of TH9 differentiation regulated anti-tumor immunity in an experimental melanoma-bearing
228 ious immunosuppressive metabolites that keep anti-tumor immunity in check, the tryptophan catabolite
239 anisms may lead to novel therapies enhancing anti-tumor immunity in the context of aging or metabolic
240 ould potentially play a role in potentiating anti-tumor immunity in the immunologically "cold" metast
241 blished tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state
242 or antibody blockade of Siglec-15 amplifies anti-tumor immunity in the TME and inhibits tumor growth
244 T cell activation, antibody production, and anti-tumor immunity in vivo, and m(6)A modification abro
245 tes cocultured T cells in vitro, compromises anti-tumor immunity in vivo, and reduces anti-tumor effi
247 on, radiotherapy also induces suppression of anti-tumor immunity, including recruitment of regulatory
248 epletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cell
249 evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolut
255 Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-base
256 Comparing irAE treatments, we find that anti-tumor immunity is preserved in mice after extracorp
260 cytoplasmic dsRNA sensing and thus promotes anti-tumor immunity mediated by cytotoxic lymphocyte act
261 sion, induce therapy resistance, and inhibit anti-tumor immunity offer clear benefits over therapies
264 he tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear.
265 r, its immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor gro
266 nd LAG-3-deficient CD8(+) T cells to enhance anti-tumor immunity, providing insight into how combinat
267 coupled with radiation therapy (RT) enhances anti-tumor immunity, reduces Treg accumulation into the
271 ng effective nanomedicines to induce durable anti-tumor immunity represents a promising strategy for
273 aptive cytotoxic effector response away from anti-tumor immunity ('sword') and towards proinflammator
274 pair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMR
275 Furthermore, treatment induces endogenous anti-tumor immunity that resisted tumor rechallenge and
276 eron pathway playing a key role in effective anti-tumor immunity, the therapeutic benefit of direct S
277 ade of MerTK-mediated phagocytosis mobilizes anti-tumor immunity through a mechanism that involves th
278 gation of additional therapies that modulate anti-tumor immunity through effects on T cells, myeloid
279 med HSPCs are sufficient to confer augmented anti-tumor immunity through production of neutrophils, m
281 e that instead impede development of desired anti-tumor immunity, thus providing synergistic effects
282 ritically important for our understanding of anti-tumor immunity to cancers that metastasize to a spe
284 role for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight
285 in the regulation of processes ranging from anti-tumor immunity to the adjuvant action of aluminum h
286 s that RNA-pulsed epidermal cells can induce anti-tumor immunity, total cellular RNA was isolated fro
287 STAT6 gene facilitates development of potent anti-tumor immunity via a CD4(+)-independent pathway.
290 independent regulatory effects STAT3 has on anti-tumor immunity, we aimed to decipher the effects of
292 nd mRNA expression for genes associated with anti-tumor immunity were obtained from the invasive brea
293 creases tumor immunogenicity and potentiates anti-tumor immunity, which has implications for cancer i
296 ron (IFN)-gamma, have been clearly linked to anti-tumor immunity, while others, such as the innate in
297 ivated CD4(+) T cells, promotes and enhances anti-tumor immunity with limited success on large tumors
298 al results, generating clinically meaningful anti-tumor immunity with STING agonists has faced substa
300 ) have been implicated in allergy/asthma and anti-tumor immunity, yet molecular insights on their dif